Bioinformatics consultancy
Nanomolar Limited gives discovery and translational teams the bioinformatics capability they need without the cost or delay of building an in-house department. We work alongside your scientists to deliver analysis, infrastructure, and reporting, from a single dataset to a complete bioinformatics function.
Scoped as a short advisory engagement, a defined analysis package, or ongoing fractional bioinformatics support.
We assess what your programmes need and build the right foundation: analysis workflows, data organisation, operating processes, and a practical hiring or outsourcing plan. Ideal for teams without in-house bioinformatics expertise or with a single analyst stretched too thin.
Practical AWS environments designed and budgeted for small biotech teams, with Nextflow workflows, containerised tools, and version-controlled analyses. Support includes instrument and laboratory data backup, Linux administration, and clear cloud cost management.
End-to-end analysis of bulk RNA-seq, proteomics, and metabolomics data, from quality control and processing through differential expression, pathway analysis, and network modelling. We integrate your internal datasets with relevant public resources to provide broader biological context, validate findings, and identify actionable hypotheses.
scRNA-seq from raw reads to annotated atlas: QC, integration across studies, cell type annotation, differential state analysis, cell–cell signalling, and Perturb-seq readouts for genetic perturbation screens.
Target identification and validation for TCR immunotherapy: antigen prioritisation across tumour and normal tissue, immunopeptidomics workflows, SNP calling and class I/II HLA typing directly from RNA-seq.
NGS analysis of phage display and library selections, binder ranking and clonotype clustering, sequence liability review, and custom sequence-analysis tooling to guide hit selection and optimisation.
Bioinformatics support for oncology and autoimmune disease programmes, including indication prioritisation, patient stratification, biomarker discovery, and resistance-mechanism analysis. We combine in vivo and preclinical study data with human evidence to inform development decisions.
Interactive portals that enable scientists to explore their own data, including R Shiny and Python Dash applications, single-cell browsers, and target dashboards. Deployed in your cloud environment with authentication and ongoing maintenance as your data grows.
Practical data capture for lab scientists: ELN selection and deployment, sample and inventory databases, structured assay results, and connection of lab output to downstream analysis so results stay findable.
A free conversation about the programme, the data you have, and the decision you need to make. If we are not the right fit, we will say so.
Fixed scope, deliverables, timeline and cost. Day rate or project fee, with an option to start small and extend.
Regular working sessions with your scientists rather than a report at the end. Analyses are reproducible and documented as they are built.
Code, pipelines, infrastructure and dashboards live in your accounts and repositories. You keep everything, and can run it without us.
Engagements are led personally by Dr Harvey Che. For larger or broader programmes we draw on a trusted network of contractors, brought in where a project needs them and always under the same delivery and confidentiality standards.
RNA-seq and scRNA-seq analysis across more than 30 public datasets to characterise disease pathways and identify genetic biomarkers, delivered with an interactive portal for the scientific team to explore the integrated data.
Built the bioinformatics function for TCR discovery and preclinical development: RNA-seq, scRNA-seq and immunopeptidomics workflows on AWS across AML and solid tumours, plus SNP calling and HLA typing from RNA-seq for patient coverage modelling, with ownership of the cloud infrastructure and budget.
Target validation and biomarker identification across rheumatoid arthritis, IBD and COPD datasets to characterise disease mechanisms and support portfolio decisions.
Analysis of a cell-based ageing model to characterise genetic perturbation effects and nominate novel anti-ageing targets.
Testimonials are available on request from Nxera Pharma, Calluna Pharma and Yellowstone Bioscience.
Tell us about the programme and the question you are trying to answer. We reply to all genuine enquiries within two working days, and the first scoping call is free.
